Gilead Sciences, Inc. (NASDAQ:GILD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Gilead Sciences, Inc. (NASDAQ:GILD) has been assigned an average rating of “Moderate Buy” from the twenty-seven analysts that are presently covering the stock, MarketBeat reports. Three investment analysts have rated the stock with a hold rating, twenty-two have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $130.6522.

GILD has been the subject of a number of research analyst reports. Citigroup raised their target price on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Wednesday, October 8th. Truist Financial initiated coverage on Gilead Sciences in a research note on Monday, November 24th. They issued a “buy” rating and a $140.00 price objective for the company. Rothschild & Co Redburn upped their target price on Gilead Sciences from $143.00 to $153.00 in a research report on Monday, November 10th. Wolfe Research raised their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, October 23rd. Finally, Needham & Company LLC lifted their price objective on shares of Gilead Sciences from $133.00 to $140.00 and gave the company a “buy” rating in a research note on Thursday, November 13th.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $125.85 on Friday. The firm has a market capitalization of $156.13 billion, a P/E ratio of 25.07, a PEG ratio of 0.81 and a beta of 0.32. Gilead Sciences has a 52 week low of $88.57 and a 52 week high of $128.70. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a 50 day moving average price of $119.87 and a 200 day moving average price of $114.59.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same quarter last year, the company posted $2.02 earnings per share. The business’s quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts expect that Gilead Sciences will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio is presently 48.99%.

Insider Buying and Selling

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of Gilead Sciences stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the completion of the transaction, the executive vice president owned 43,676 shares in the company, valued at approximately $5,365,596.60. This trade represents a 55.12% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the sale, the chief financial officer owned 154,555 shares in the company, valued at $19,354,922.65. The trade was a 1.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 115,146 shares of company stock valued at $14,012,141 over the last quarter. 0.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in GILD. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the period. Corundum Trust Company INC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at about $26,000. Activest Wealth Management raised its holdings in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in Gilead Sciences during the second quarter worth approximately $27,000. Finally, Howard Hughes Medical Institute acquired a new stake in Gilead Sciences in the second quarter valued at approximately $30,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.